Richard Pestell

Richard Pestell began his medical journey at the University of Western Australia, where he graduated at the top of his class and earned an M.B., B.S., with a strong commitment. He continued his clinical training as a physician in training at the Royal Perth Hospital and St Vincent's Hospital, Sydney. These years provided intensive experience in Internal Medicine and residency, including oncology, endocrinology, hematology, cardiology, and transplant medicine.

He pursued cancer biology through advanced research, culminating in a Ph.D. from the University of Melbourne at the Howard Florey Institute, specializing in oncogene regulation of gene transcription. National scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award, supported his academic excellence. These achievements led him to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow.

Richard continued his academic career at Northwestern University and later at the Albert Einstein College of Medicine. He became a Professor, Chair of the Division of Endocrine Dependent Tumor Biology, and Co-Director of major cancer research programs. He also held positions at multiple hospitals in New York, which helped him stay engaged in patient care and medical education while contributing to scientific programs in cancer biology.

Richard Pestell’s research helped lay the foundation for cancer therapeutics and for translating discoveries into clinical trials. His research on cyclin D1 was cited in the seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. His work on CCR5 provided the scientific framework for current oncology clinical trials with CCR5 inhibitors. His contributions include over 700 publications, more than 110,000 citations, an h-index of 162, and extensive invited lecture engagements worldwide.

In 2002, he became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University. He also served as Chair of the Department of Oncology and as Associate Vice President at Georgetown University Medical Center. In this capacity, he was responsible for research, clinical operations, and faculty development, and he was involved in institutional restructuring and growth. He built community partnerships, enhanced research programs, and expanded clinical services across Georgetown and MedStar systems.

Richard took on significant leadership roles in 2005 as the Director of the Sidney Kimmel Cancer Center, Chair of the Department of Cancer Biology, and head of the Oncology Service Line at Thomas Jefferson University. He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of >$350m and led transformational efforts in clinical care, research infrastructure, regional expansion, and team building. The cancer center went from 64th to 17th under his tenure. He achieved significant progress.

Richard Pestell held leadership roles in academia outside of the US and contributed to research, education, and outreach initiatives. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. He also served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions.

He has served with prominent scientific bodies, including the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion and the Eric Susman Prize in Medicine, culminating in his being made an Officer of the Order of Australia in 2019. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors, plus more than 80 million dollars as a principal investigator on NIH research grants.

Richard Pestell has also emphasized philanthropy, community service, and cultural engagement. At Georgetown and at Jefferson, he led philanthropic efforts that produced transformational gifts and created new ways to sustain ongoing fundraising in support of cancer care, wellness centers, and community outreach initiatives. He has served on boards including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. He supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. Richard now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, as the Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and as a member of the Wistar Institute Cancer Center. He still supports global cancer programs, mentors scientific leaders, and develops technologies for improved diagnostics and treatment.